Effects of dry needling trigger points in the treatment of primary trigeminal neuralgia

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500101386

Enrollment

Unknown

Registered

2025-04-24

Start date

2025-05-01

Completion date

Unknown

Last updated

2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary trigeminal neuralgia

Interventions

Dry needling group:dry needling trigger points

carbamazepine group:Oral administration of carbamazepine

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Those who meet the diagnostic criteria for primary trigeminal neuralgia and are over 18 years old; (2) Patients without obvious organic lesions detected by cranial MRI; (3) Pain has been occurring every day in the past month, with an average VAS score of >= 4 points in the past 48 hours (0 points no pain, 10 points most painful), and if the patient used carbamazepine at the time of enrollment, the average VAS score in the past 48 hours is <= 8 points; (4) Patients aged 18-75 years old; (5) Individuals who have not undergone surgery related to primary trigeminal neuralgia in the past; (6) Patients who sign informed consent forms and voluntarily participate in this project. Only those who meet the above six criteria can be included in this study.

Exclusion criteria

Exclusion criteria: (1) Patients with secondary trigeminal neuralgia caused by other diseases such as intracranial tumors, multiple sclerosis, etc; (2) Patients with painful trigeminal neuralgia caused by herpes zoster, trauma, etc; (3) Patients with facial pain caused by other diseases such as glossopharyngeal neuralgia, temporomandibular joint disorders, sinusitis, apical periodontitis, and cranial neuropathy; (4) Breastfeeding or pregnant women; (5) Patients with severe comorbidities or poorly controlled underlying diseases; (6) Patients with four positive infections, severe coagulation dysfunction, and significant platelet abnormalities; (7) Currently participating in other medical trials. Anyone who meets any of the above criteria shall be excluded.

Design outcomes

Primary

Measure	Time frame
visual analogue scale;	—

Secondary

Measure	Time frame
Frequency of pain in patients;Douleur Neuropathique 4 questions DN4;Pain Catastrophizing Scale;medication intake;Trigger point tenderness threshold(PPT);GAD-7;PHQ-9;Pittsburgh Sleep Quality Index, PSQI;	—

Countries

China

Contacts

Public ContactYantao Ma

Huadong Hospital, Fudan University

mayantao1102@163.com+86 158 0085 9381

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026